Skip to main content
SpringerLink
Log in

Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance

  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

The anti-inflammatory, analgesic and antipyretic properties of the new non-steroidal anti-inflammatory agent, meloxicam, were investigated in a variety of animal models and compared with the properties of piroxicam, diclofenac, indomethacin and several other NSAIDs.

With respect to the total effect of a single oral dose, the anti-exudative effect of meloxicam on carrageenaninduced oedema in the rat exceeded that of all the NSAIDs included in the comparison. Additionally, meloxicam showed the greatest potency of all the compounds examined with respect to adjuvant-induced arthritis in the rat, the granuloma pouch model and the cotton pellet test in the rat. Unlike indomethacin, in the carrageenan pleurisy model in the rat, meloxicam caused both a dose-dependent reduction in exudate volume and also inhibition of leucocyte migration.

Meloxicam showed a strong and lasting effect on inflammatory pain in the rat. Like other NSAIDs, but unlike dipyrone, meloxicam had no effect in the hot plate and tail clamp tests, which are used to identify weak central analgesic effects. Unlike dipyrone and like indomethacin, meloxicam had no effect in a model of visceral distention pain.

In common with other NSAIDs, meloxicam had no influence on the body temperature of normothermic rats in the anti-inflammatory dose range, but did reduce yeastinduced fever in the rat in a dose-dependent manner. Like piroxicam, meloxicam had a uricosuric effect on rats treated with oxonic acid.

Low-dose meloxicam inhibited both bradykinin-induced and PAF-induced bronchospasm in the guinea-pig, but had no effect on acetylcholine-induced bronchospasm.

Piroxicam had greater ulcerogenic effects in the rat stomach than meloxicam.

The therapeutic range of meloxicam in the rat, with regard to inhibition of adjuvant arthritis, was several times greater than that of piroxicam, indomethacin, diclofenac and naproxen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vane JR. Towards a better aspirin. Nature 1994;367:215–6.

    PubMed  Google Scholar 

  2. Engelhardt G. Meloxicam inhibits preferentially COX-2. Europ J Clin Pharmacol 1994;47:A98.

    Google Scholar 

  3. Engelhardt G, Bögel R, Krug I, Walcher I. Meloxicam: Lack of correlation between inhibition of PG biosynthesis in the inflammatory area and in the stomach. Magy Rheumatol 1991;32(Suppl):354.

    Google Scholar 

  4. Busch U. Pharmacokinetics of meloxicam in animals. Scand J Rheumatol 1994;(Suppl)98:A119.

    Google Scholar 

  5. Türk D, Busch U, Heinzel G, Narjes H. Basic clinical pharmacokinetic of meloxicam, a new NSAID. Scand J Rheumatol 1994;(Suppl)98:A120.

    Google Scholar 

  6. Engelhardt G, Trummlitz G. Biological activity of the main metabolites of meloxicam. Drugs Exptl Clin Res 1990;16:53–6.

    Google Scholar 

  7. Doepfner W, Cerletti A. Comparison of lysergic acid derivatives and antihistamines as inhibitors of the edema provoked in the rat's paw by serotonin. Int Archs Allergy Appl Immunol 1958;12:90–7.

    Google Scholar 

  8. Hillebrecht J. Zur routinemäßigen Prüfung antiphlogistischer Substanzen im Rattenpfotentest. Arzneim Forsch 1954;4:607–14.

    Google Scholar 

  9. Linder A. Statistische Methoden. 4th ed, Basel, Birkhäuser, 1964:148–62.

  10. Fieller EC. A fundamental formula in the statistics of biological assay and some applications. Quart J Pharmac Pharmacol 1944;17:117–23.

    Google Scholar 

  11. Winter CHA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc Soc Exper Biol Med 1962;111:544–7.

    Google Scholar 

  12. Wilhelmi G, Domenjoz R. Die Beeinflussung des Hühnereiweiß-Oedems an der Rattenpfote durch Pyrazole sowie Cortison und ACTH. Arzneim Forsch 1951;1:151–4.

    Google Scholar 

  13. Selye H. Use of “granuloma pouch” technique in the study of antiphlogistic corticoids. Proc Soc Exper Biol Med 1953;82:328–33.

    Google Scholar 

  14. Newbould BB. Chemotherapy in arthritis induced in rats by mycobacterial adjuvant. Brit J Pharmacol 1963;21:127–36.

    Google Scholar 

  15. Garland LG, Smith SJ, Sim MF. A device for the rapid measurement of rat foot volume. J Pharm Pharmacol 1968;20:236–8.

    PubMed  Google Scholar 

  16. Vinegar R, Truax JF, Selph JL. Some quantitative temporal characteristics of carrageenin-induced pleurisy in the rat. Proc Soc Exp Biol Med 1973;143:711–4.

    PubMed  Google Scholar 

  17. Meier R, Schuler W, Desaulles P. Zur Frage des Mechanismus der Hemmung des Bindegewebewachstums durch Cortisone. Experientia 1950;6:469–71.

    PubMed  Google Scholar 

  18. Randall LO, Selitto JJ. A method for measurement of analgesic activity on inflammation tissue. Arch Int Pharmacodyn 1957;111:409–19.

    PubMed  Google Scholar 

  19. Chen JYP, Beckman H. A satisfactory apparatus for study of analgesia in mice. Science 1951;113:631.

    Google Scholar 

  20. Finney DJ. Probit Analysis. 3rd ed. Cambridge: Cambridge University Press, 1971.

    Google Scholar 

  21. Haffner F. Experimentelle Prüfung schmerzstillender Mittel. Dtsch Med Wschr 1929;54:731–3.

    Google Scholar 

  22. Lembeck F, Skofitsch G. Visceral pain reflex after pretreatment with capsaicin and morphine. Naunyn-Schmied Arch Pharmakol 1982;312:116–22.

    Google Scholar 

  23. Domenjoz, R. The pharmacology of phenylbutazone analogues. Ann NY Acad Sci 1960;86:263–91.

    Google Scholar 

  24. Johnson WJ, Stavric B, Chartrand A. Uricase inhibition in the rat by s-triazines: An animal model for hyperuricemia and hyperuricosuria. Proc Soc Exp Biol Med 1969;131:8–12.

    PubMed  Google Scholar 

  25. Kern A, Stransky E. Beitrag zur kolorimetrischen Bestimmung der Harnsäure. Biochem Zeitschr 1937;290:419–27.

    Google Scholar 

  26. Konzett H, Rössler R. Versuchsanordnung zu Untersuchungen an der Bronchialmuskulatur. Naunyn-Schmied Arch Pharmakol 1940;195:71–4.

    Google Scholar 

  27. Collier HOJ, Shorley PG. Analgesic antipyretic drugs as antagonists of bradykinin. Br J Pharmacol 1960;15:601–10.

    Google Scholar 

  28. Mörsdorf K, Anspach K. Zur Wirkungspontenz verschiedener Antiphlogistika bei der Carrageenin-entzündung in Vergleich zu anderen Entzündungsmodellen. Arch Int Pharmacodyn 1971; 192:111–27.

    PubMed  Google Scholar 

  29. Boudinot SG, Funderburg ED, Boudinot FD. Effects of age on the pharmacokinetics of piroxicam in rats. J Pharmacol Sci 1993;82:254–7.

    Google Scholar 

  30. Ward JR, Cloud S. Comparative effect of antirheumatic drugs on adjuvant-induced polyarthritis in rats. J Pharmacol Exp Ther 1966;152:116–21.

    PubMed  Google Scholar 

  31. Engelhardt G. Meloxicam: A potent inhibitor of adjuvant arthritis in the rat. Scand J Rheumatol 1994;(Suppl)98:A110.

    Google Scholar 

  32. Busch U, Engelhardt G. Distribution of [14C] meloxicam in joints of rats with adjuvant arthritis. Drugs Exptl Clin Res 1990;16:49–52.

    Google Scholar 

  33. Rivkin I, Foschi GV, Rosen CH. Inhibition of in vitro neutrophil chemotaxis and spontaneous motility by antiinflammatory agents. Proc Soc Exp Biol Med 1976;153:236–40.

    PubMed  Google Scholar 

  34. Otterness IG, Larson DL, Lombardino JG. An analysis of piroxicam in rodent models of arthritis. Agents Actions 1982;12:308–12.

    PubMed  Google Scholar 

  35. Fauci AS, Dale DC, Balow JE. Glucocorticoid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976;84:304–15.

    PubMed  Google Scholar 

  36. Di Rosa M. Inhibition of cell migration and granuloma formation. In: Anti-inflammatory drugs. Handbook of Experimental Pharmacology. Berlin-Heidelberg-New York: Springer, 1979:50/II,223–54.

    Google Scholar 

  37. Fukuhara M, Tsurufuji S. The effect of locally injected antiinflammatory drugs on the synthesis of collagen and noncollagen protein in carrageenin granuloma in rats. Biochem Pharmacol 1969;18:2409–14.

    PubMed  Google Scholar 

  38. Vane JR. Mode of action of aspirin and similar compounds. In: Robinson HJ, Vane JR, editors. Prostaglandin synthetase inhibitors. New York: Raven Press, 1974:155–64.

    Google Scholar 

  39. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992;257:1276–9.

    PubMed  Google Scholar 

  40. Swingle KF. Evaluation of antiinflammatory activity. In: Scherer RA, Whitehouse MW, editors. Antiinflammatory agents. New York-San Francisco-London: Academic Press, 1974.

    Google Scholar 

  41. Collier HOJ, Holgate JA, Schachter M, Shorley PG. An apparent bronchoconstrictor action of bradykinin and its suppression by some anti-inflammatory drugs. J Physiol 1959;149:54P–5.

    Google Scholar 

  42. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin peroxides. Proc Natl Acad Sci USA 1975;72:2994–8.

    PubMed  Google Scholar 

  43. Lefort J, Rotilio D, Vargaftig BB. The platelet-independent release of thromboxane A2 by PAF-acether from guinea-pig lungs involves mechanisms distinct from those for leukotrienes. Br J Pharmacol 1984;82:565–75.

    PubMed  Google Scholar 

  44. Voelkel NF, Worthen S, Reeves JT, Henson PM, Murphy RC. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science 1982;218:286–8.

    PubMed  Google Scholar 

  45. Wynne HA, Rawlins MD. Are systemic levels of non steroidal antiinflammatory drugs relevant to an acute upper gastrointestinal haemorrhage. Eur J Clin Pharmacol 1993;44:309–13.

    PubMed  Google Scholar 

  46. Kaufman DW, Kelly JP, Sheenan JE, Laszlo A. Wilholm BE, Alfredsson L, et al. Non-steroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993;53:485–94.

    PubMed  Google Scholar 

  47. Langman FJS, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RFA, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075–8.

    PubMed  Google Scholar 

  48. Djahanguiri B. The production of acute gastric ulceration by indomethacin in the rat. Scand J Gastroenterol 1969;4:265–7.

    PubMed  Google Scholar 

  49. Dearden JC, Nicholson RM. Correlation between gastric irritancy and anti-inflammatory activity of non-steroidal antiinflammatory drugs. J Pharmac Pharmacol 1984;36:713–5.

    Google Scholar 

  50. Lehmann HA, Baumeister M, Lützen L, Wiegleb J. Meloxicam: A toxicology overview. Scand J Rheumatol 1995. In press.

  51. Whittle BJR, Vane JR. A biochemical basis for the gastrointestinal toxicity of non-steroid antirheumatic drugs. Arch Toxicol 1984;7(Suppl):315–22.

    Google Scholar 

  52. Szabo S. Mechanisms of gastric mucosal injury and protection. J Clin Gastroenterol 1991;13(Suppl 2):S21–34.

    PubMed  Google Scholar 

  53. Whittle BJR, Higgs GA, Eakins KE, Moncada S, Vane JR. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980;284:271–3.

    PubMed  Google Scholar 

  54. Green JR, Böttcher I, Peskar BA. Effect of a new antiinflammatory compound, CGP 28237, on arachidonate metabolism in rat gastrointestinal tissue. Agents Actions 1988;23:110–1.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacologic Research, Dr. Karl Thomae GmbH, D-88397, Biberach/Riss, Germany

    G. Engelhardt, D. Homma, K. Schlegel, R. Utzmann & C. Schnitzler

Authors
  1. G. Engelhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Homma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Schlegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Utzmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Schnitzler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Engelhardt, G., Homma, D., Schlegel, K. et al. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 44, 423–433 (1995). https://doi.org/10.1007/BF01757699

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01757699

Key words

Search

Navigation